Ventyx Other Stockholder Equity from 2010 to 2025

VTYX Stock  USD 1.23  0.01  0.82%   
Ventyx Biosciences Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity will likely drop to about 449.5 M in 2025. During the period from 2010 to 2025, Ventyx Biosciences Other Stockholder Equity regression line of annual values had r-squared of  0.62 and arithmetic mean of  181,433,956. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
808.2 M
Current Value
449.5 M
Quarterly Volatility
290.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ventyx Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ventyx Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 14.1 M, Depreciation And Amortization of 135.1 K or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.62. Ventyx financial statements analysis is a perfect complement when working with Ventyx Biosciences Valuation or Volatility modules.
  
Check out the analysis of Ventyx Biosciences Correlation against competitors.
For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.

Latest Ventyx Biosciences' Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Ventyx Biosciences over the last few years. It is Ventyx Biosciences' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ventyx Biosciences' overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Ventyx Other Stockholder Equity Regression Statistics

Arithmetic Mean181,433,956
Geometric Mean2,738,431
Coefficient Of Variation159.98
Mean Deviation248,992,065
Median199,000
Standard Deviation290,260,655
Sample Variance84251.2T
Range808M
R-Value0.79
Mean Square Error34619.4T
R-Squared0.62
Significance0.0003
Slope47,869,211
Total Sum of Squares1263768.7T

Ventyx Other Stockholder Equity History

2025449.5 M
2024808.2 M
2023663.2 M
2022581.2 M
2021397.1 M
20201.8 M

About Ventyx Biosciences Financial Statements

Ventyx Biosciences investors use historical fundamental indicators, such as Ventyx Biosciences' Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Ventyx Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity808.2 M449.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Ventyx Stock Analysis

When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.